Literature DB >> 15461897

Waiting to inhale: noninjectable insulin, are we there yet?

Kjeld Hermansen1.   

Abstract

Subcutaneous injection has been the only route of insulin administration for patients with type 1 or type 2 diabetes for the past 80 years. Although research and development in this time has improved the insulin treatments themselves, it is only now that alternative routes of insulin administration are becoming viable. Many avenues of insulin administration have been explored, including oral, buccal, and pulmonary routes. However, these methods of noninvasive insulin delivery are not free from difficulties and only preliminary data are available for oral insulin pills and buccal insulin sprays. The most promising alternative route of delivery appears to be inhaled insulin and two devices are already in phase III testing. Nevertheless, inhaled insulin devices will still have to overcome some problems and recent studies show that these challenges are currently being confronted. It appears that years of research into noninvasive methods of insulin administration are close to fruition and this review outlines the most recent findings in this area.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15461897     DOI: 10.1007/s11892-004-0034-4

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  45 in total

1.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

2.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

Authors:  M Shichiri; H Kishikawa; Y Ohkubo; N Wake
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

3.  Inhaled human insulin treatment in patients with type 2 diabetes mellitus.

Authors:  W T Cefalu; J S Skyler; I A Kourides; W H Landschulz; C C Balagtas; S Cheng; R A Gelfand
Journal:  Ann Intern Med       Date:  2001-02-06       Impact factor: 25.391

4.  The impact of smoking on inhaled insulin.

Authors:  Anders Himmelmann; Johan Jendle; Anders Mellén; Astrid H Petersen; Ulf L Dahl; Per Wollmer
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

5.  Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison.

Authors:  Robert R Henry; Sunder Mudaliar; Neelima Chu; Dennis Kim; Debra Armstrong; Trent T Davis; Bob An; Rickey R Reinhardt
Journal:  J Clin Pharmacol       Date:  2003-11       Impact factor: 3.126

6.  Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.

Authors:  Jaime Guevara-Aguirre; Marco Guevara; Jeannette Saavedra; Marko Mihic; Pankaj Modi
Journal:  Diabetes Technol Ther       Date:  2004-02       Impact factor: 6.118

7.  Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Authors: 
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

8.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  In vitro permeability of PBCA nanoparticles through porcine small intestine.

Authors:  D Scherer; F C Mooren; R K Kinne; J Kreuter
Journal:  J Drug Target       Date:  1993       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.